MIM
VIRX

MetLife Investment Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

MetLife Investment Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,069
Closed -$40.7K – 2565
2021
Q3 		$40.7K Sell
5,069
-9,638
-66% -$95K ﹤0.01% 2539
2021
Q2 		$167K Buy
+14,707
New +$148K ﹤0.01% 2265

Other funds holding VIRX

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MetLife Investment Management's VIRX Position: Q4 2021 in Review

MetLife Investment Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2021, closing a stake of 5,069 shares — an estimated $40.7K sold.

MetLife Investment Management first reported a position in VIRX in Q2 2021 and held it in 2 quarters. The position peaked at $167K in Q2 2021. 69 funds tracked by Wall St. Rank hold VIRX as of Q4 2021.

  • MetLife Investment Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • MetLife Investment Management sold 5,069 Viracta Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $40.7K.
  • MetLife Investment Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • MetLife Investment Management's Viracta Therapeutics, Inc. Common Stock position peaked at $167K in Q2 2021.
  • 69 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2021.

Based on MetLife Investment Management's 13F filing for Q4 2021, filed 15 Feb 2022.